Objective To study the effect of PCSK9 inhibitor on oxidized low density lipoprotein (ox-LDL) and blood lipid profile in patients with cardiovascular diseases.Methods Clinical data were retrospectively collected from 274 patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) diagnosed in our hospital.The patients were divided into an evolocumab group (117 patients) and a statin monotherapy group (157 patients) according to the use of evolocumab (a PCSK9 inhibitor) or not after percutaneous coronary intervention (PCI).The levels of ox-LDL,total cholesterol (TC),triglycerides (TG),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C),and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups on admission and after 2 weeks of treatment.Results After 2 weeks of treatment,the levels of ox-LDL,TC,and TG were significantly lower in the evolocumab and statin monotherapy groups than before treatment (P＜0.05).The reduction of ox-LDL,TC and TG levels was more significant in the evolocumab group than in the statin monotherapy group (P＜0.05).Conclusion PCSK9 inhibitors can reduce the levels of ox-LDL and lipid parameters in very high-risk ASCVD patients in a short period of time.
维普
万方数据